A widely used joint supplement may be associated with faster progression of Alzheimer's disease, according to a large analysis of health records. The study found that people who took glucosamine were about 25% more likely to see mild cognitive impairment advance to dementia than those who did not use the supplement.
The finding, drawn from a substantial set of patient records, adds a note of caution to a product taken by millions of people for knee, hip, and other joint pain. Glucosamine is one of the most popular over-the-counter supplements in the United States and is often assumed to be harmless because it is sold without a prescription.
Researchers stress that the health-record analysis can only show an association, not cause and effect. People who use glucosamine may differ in other ways that influence dementia risk, and the data cannot rule out such confounding factors. To probe a possible mechanism, the team turned to laboratory experiments.
Those experiments suggest glucosamine may intensify an abnormal sugar-tagging process in the brain that has been linked to Alzheimer's disease. In the Alzheimer's brain, proteins can acquire excess sugar molecules in a process that is thought to contribute to the damage underlying the condition. The lab work indicates that glucosamine may accelerate or amplify this process, offering a biological explanation for why the supplement could be tied to faster decline.
Even so, the researchers say clinical trials are needed before any conclusion can be drawn about whether glucosamine actually causes harm. Observational data and laboratory findings are important early signals, but they cannot establish that the supplement itself worsens Alzheimer's progression in patients.
The results are likely to draw attention from neurologists, geriatricians, and patients with mild cognitive impairment, a condition that often precedes dementia. Mild cognitive impairment involves noticeable problems with memory or thinking that are greater than expected for a person's age but do not yet interfere substantially with daily life. Each year, a portion of people with the condition progress to dementia, and identifying factors that speed or slow that transition is a major goal of Alzheimer's research.
Glucosamine supplements are typically marketed for joint health and are frequently used by older adults, the same population that faces the highest risk of cognitive decline. That overlap makes the question of long-term cognitive effects especially relevant for public health, even though the current evidence remains preliminary.
The study authors are not advising patients to stop taking glucosamine based on these findings alone. Instead, they emphasize that randomized controlled trials, which can test cause and effect, are the necessary next step. Until such trials are conducted, the link between glucosamine and faster Alzheimer's progression remains a hypothesis supported by suggestive but not definitive evidence.
For now, the research adds to a growing body of work examining how common supplements and medications may influence the course of neurodegenerative disease. It also underscores a recurring theme in Alzheimer's research: promising signals from health records and laboratory models must be confirmed in human trials before they change clinical practice.
13
